- Home
- RQI vs XERS Comparison
RQI vs XERS Comparison
Compare RQI & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RQI | XERS |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RQI | XERS |
|---|---|---|
| Price | $11.15 | $9.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 643.3K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | N/A | $22.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $11.16 | $5.25 |
| 52 Week High | $13.57 | $10.08 |
Technical Indicators
Market Signals| Indicator | RQI | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 24.41 | 64.28 |
| Support Level | N/A | $7.15 |
| Resistance Level | $13.47 | N/A |
| Average True Range (ATR) | 0.19 | 0.44 |
| MACD | -0.04 | 0.12 |
| Stochastic Oscillator | 9.31 | 93.89 |
Price Performance
Historical ComparisonAbout RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. The Fund's secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.